AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05419752
Drug: MTA
RxNorm normalized name: HMTA
DrugBank: 5'-S-methyl-5'-thioadenosine (DB02282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTA based obturating sealer
Trial: NCT05419752
Drug: resin sealer
RxNorm normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: resin based obturating sealer
Trial: NCT04781816
Drug: SAR443122
RxNorm normalized name: SAR443122
DrugBank: SAR443122 (DB16492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule Route of administration: Oral
Trial: NCT05124353
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin 30ml i.v., administrated in first 6 hours after stroke onset and fo 10 day afterwards in Neurology Department or ICU conditions.
Trial: NCT06607991
Drug: Blinatumomab Treatment
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Blinatumomab treatment for CNI-resistant/Intolerant pediatric steriod-resistant nephrotic syndrome Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Trial: NCT06716853
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40mg QD once PD occurs as assessed at D+30 or at subsequent visits
Trial: NCT05020496
Drug: Diphenylcyclopropenone (DPCP)
RxNorm normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be applied topically on the skin. It will cause contact hypersensitivity in patients
Trial: NCT06028828
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given Day-5, Day-4, Day-3, Day-2
Trial: NCT06028828
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given Day-5
Trial: NCT04691388
Drug: sintilimab combined with anlotinib
RxNorm normalized name: miconazole
DrugBank: Anlotinib (DB11885)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive sintilimab combined with anlotinib every 3 weeks
Trial: NCT04927481
Drug: Mitoxantrone Hydrochloride Liposome Injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone Hydrochloride Liposome 20 mg/m2, IV, on day 1 of each 21-day cycle (q3w).
Trial: NCT06626503
Drug: Methadone based ERAS
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children randomized to the methadone arm will receive standardized perioperative care and analgesia, including intraoperative intravenous methadone (0.1 mg/kg up to a maximum of 5 mg before incision and 0.05 mg at the end of surgery) and postoperatively, up to 4 oral doses of methadone every 12 hours before discharge as part of standardized multimodal analgesia in the hospital setting.
Trial: NCT05780879
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax administered orally once daily on days 3-16.
Trial: NCT06626503
Drug: SOC non-methadone based group
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children randomized to the standard-of-care arm will receive standard opioid analgesia protocol without intra- and post-operative methadone per the current site standards.
Trial: NCT06218810
Drug: Cadonilimab + bevacizumab + FOLFOX
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cadonilimab + bevacizumab + FOLFOX
Trial: NCT06487299
Drug: Ferrous Lactate
RxNorm normalized name: Ferrous lactate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injection solution was 3 ferrous lactate (10ml:0.1g iron) mixed with 20ml saline.
Trial: NCT06487299
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The injection was 3 shots of ferrous lactate (5ml:100mg iron) mixed with 35ml saline.
Trial: NCT06462287
Drug: Aprepitant 125 and 80Mg Oral Capsule
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 1 oral capsule time a day for 4 days (First day: 125 mg and the 3 last days: 80 mg)
Trial: NCT04982991
Drug: RIPK1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule Oral
Trial: NCT06452771
Drug: ALN-ANG3
RxNorm normalized name: ARO-ANG3
DrugBank: ARO-ANG3 (DB17626)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC) injection
Trial: NCT05788601
Drug: Dapiglutide
RxNorm normalized name: Dapiglutide
DrugBank: Dapiglutide (DB19182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1/GLP-2 receptor agonism
Trial: NCT05914194
Drug: NLS-2
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive NLS-2 tablets orally.
Trial: NCT04903626
Drug: Glecaprevir/Pibrentasvir (GLE/PIB)
DrugBank: Pibrentasvir (DB13878)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablets
Trial: NCT05171972
Drug: Ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This investigator-initiated study will be carried out secondary to the discussion of treatment with Ofatumumab and thus our study will not influence or impact the determination of the suitability for candidates to commence therapy with Ofatumumab. This decision will be made by the patient's physician as part of the patient's standard care, and will occur independently of this study. Patients to be enrolled in this longitudinal study will only be asked if they would like to take part if their clinician independently chooses Ofatumumab as a treatment option.
Trial: NCT05362292
Drug: Tolterodine Tartrate ER
RxNorm normalized name: Tolterodine Tartrate ER
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anticholinergic
Trial: NCT05362292
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Beta-3-adrenergic agonist
Trial: NCT06340230
Drug: SHR-A1811 Injection + Adebrelimab Injection
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A1811 Injection Drug: Adebrelimab Injection
Trial: NCT06340230
Drug: SHR-A1811 Injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: SHR-A1811 Injection
Trial: NCT04792190
Drug: dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will take 1 blinded tablet of study drug (dapagliflozin 10 mg) dosed once daily, for 12 months.
Trial: NCT06646952
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Trial: NCT05200559
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.
Trial: NCT05200559
Drug: E7777
RxNorm normalized name: Elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
Trial: NCT05962255
Drug: Furosemide intravenous infusion
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At baseline, patients will receive a standardised dose of furosemide 1mg/kg (half of the dose administered as bolus and half as in 2h infusion).~At the 6th and the 12th hour of the study patients will be reassessed and the need for additional diuretics.
Trial: NCT05962255
Drug: Continous intravenous infusion of 0.9% Sodium Chloride solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous 48h infusion of 0.9% sodium chloride at a fixed rate v= 83 ml/h x 24h = 2l/24h
Trial: NCT05376722
Drug: pamiparib
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pamiparib 40 mg orally, twice a day
Trial: NCT05376722
Drug: abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biraterone acetate 1000 mg orally, once a day
Trial: NCT05376722
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisone acetate tablets (prednisone) 5 mg, once a day
Trial: NCT05414175
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06613880
Drug: standard IST combined with Romiplostim N01
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim N01 is a class of TPO receptor agonists. Its TPO peptide can bind to TPO receptors on megakaryocyte precursors in the bone marrow and activate them, triggering a series of intracellular signalling pathways, including JAK2/STAT5, PI3K/Akt, MEK/ERK, and p38, which ultimately lead to gene transcription and increased megakaryocyte proliferation and differentiation.
Trial: NCT06614036
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Byfavo 20 mg powder for solution for injection, remimazolam. Each vial contains remimazolam besylate equivalent to 20 mg remimazolam. Concentration after reconstitution: 2.5 mg/ml.
Trial: NCT06614036
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 1mg/ml, solution for injection / infusion. Each 5ml ampoule contains 5mg midazolam. Concentration: 1mg/ml.
Trial: NCT04761198
Drug: Etigilimab
RxNorm normalized name: Etigilimab
DrugBank: Etigilimab (DB18854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of IV etigilimab every 2 weeks
Trial: NCT04761198
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion of nivolumab every 2 weeks
Trial: NCT06717464
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240mg intravenous injection, q3w, for 54 weeks (18 cycles)
Trial: NCT06714838
Drug: Rituximab (Mabthera)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered in a hospital setting in the course of one day. It will be given intravenously, at time points baseline, week 2 and week 26.
Trial: NCT05393245
Drug: Tiotropium+Olodaterol
RxNorm normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium+Olodaterol
Trial: NCT05823896
Drug: Nirmatrelvir/ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300/100 mg tablet twice daily (q12h) administered orally for 15 days
Trial: NCT05823896
Drug: Placebo/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg tablet twice daily (q12h) administered orally for 15 days
Trial: NCT05821452
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mgQ3w
Trial: NCT05821452
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 175mg/m2，D1，Q3w
Trial: NCT05821452
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2，D1，Q3w
Trial: NCT03924492
Drug: ZULRESSO (brexanolone) injection
RxNorm normalized name: Zulresso
DrugBank: Brexanolone (DB11859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZULRESSO
Trial: NCT05542446
Drug: Colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 1 - screening - Patient selection phase. Patients meeting the eligibility criteria will be screened if not meeting any of the exclusion criteria. A pregnancy test from a urine test will be performed on women of childbearing potential. The patient will be offered participation in the clinical trial and interviewed by the investigator.~Visit 2 (Visit 8, Visit 14 - optional, only if colistin is still indicated) - CMS administration The patient will be hospitalized at FNUSA. CMS will be given intravenously via the central vein catheter (a loading dose of 9 MIU intravenously over 30 minutes followed after 12 hours by a maintenance dose of 4,5 MIU intravenously over 30 minutes every 12 hours; only in patients requiring continuous renal replacement methods will the interval of the maintenance doses be 8 hours).~Visit 3 - Visit 7 (Visit 9-Visit 13, Visit 15-Visit 19 - optional, only if colistin is still indicated) - Pharmacokinetics blood samples collection.
Trial: NCT04762082
Drug: Tadalafil 10 MG
RxNorm normalized name: tadalafil 10 MG
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of tadalafil gummy 10mg and tadalafil oral tablet 10mg
Trial: NCT04963816
Drug: Dexamethasone Phosphate 4 MG/ML Injectable Solution intravenously
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given intravenously in group A
Trial: NCT04963816
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine will be given to all groups locally with QLB
Trial: NCT04963816
Drug: Dexamethasone Phosphate 4 MG/ML Injectable Solution locally
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Using dexamethasone as an adjuvant to bupivacaine in ultrasound guided quadratus lumborum block which will be given locally in Group B
Trial: NCT04753489
Drug: Rivaroxaban film-coated tablet 10 mg
RxNorm normalized name: rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 10 mg of rivaroxaban.
Trial: NCT00002143
Drug: Acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04418895
Drug: fluoropyrimidine +/- oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: possible adjuvant chemotherapy regimen. Subjects who do not receive preoperative mFOLFOX6 or CAPOX typically receive postoperative adjuvant chemotherapy with a fluoropyrimidine +/- oxaliplatin for an additional 16-18 weeks of therapy, if permitted based on recovery after surgical resection and post-surgical performance status. This treatment is at the discretion of the treating medical oncologist. Subjects will remain on study regardless of postoperative therapy administration or duration.
Trial: NCT05200312
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg capsules administered by mouth twice daily (21-day cycles).
Trial: NCT05200312
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25 mg capsules administered by mouth once daily on Day 1 to Day 10 of each cycle (21-day cycles)
Trial: NCT05200312
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT05200312
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Trial: NCT05200312
Drug: Prednisone (or equivalent)
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
Trial: NCT05979961
Drug: gemcitabine and cisplatin (Induction chemotherapy)
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy
Trial: NCT05187260
Drug: Nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SPINRAZA® (nusinersen) prescribed as part of standard of care
Trial: NCT04800393
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction of anesthesia with propofol, maintenance of anesthesia with sevoflurane during breast cancer surgery
Trial: NCT04800393
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: propofol-based total intravenous anesthesia during breast cancer surgery
Trial: NCT04991493
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-tramadol group: 1mg/kg of tramadol will be intravenously injected 15 minutes before anesthesia.~post-tramadol group: 1mg/kg of tramadol will be intravenously injected when the incision was washed and sutured.
Trial: NCT04924621
Drug: Midazolam(T group)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 0.05mg/kg, intravenous injection
Trial: NCT04924621
Drug: Propofol(T group)
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 2-3ug/ml, intravenous injection
Trial: NCT04924621
Drug: Rocuronium(T group)
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.06mg/kg, intravenous injection
Trial: NCT04924621
Drug: Midazolam(C group)
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 0.05mg/kg, intravenous injection
Trial: NCT04924621
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1-2ug/ml, intravenous injection
Trial: NCT04924621
Drug: Tetracaine(C group)
RxNorm normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2ml tetracaine was injected with cyclothyroid membrane puncture.
Trial: NCT05073939
Drug: Oral Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of oxytocin (24 international units) orally
Trial: NCT06003777
Drug: PF-06954522
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.
Trial: NCT05836272
Drug: Norepinephrine Bitartrate
RxNorm normalized name: Norepinephrine Bitartrate
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.~Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.
Trial: NCT00893854
Drug: Triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05698303
Drug: Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
RxNorm normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT103A is an BCMA targeted genetically modified autologous T cell immunotherapy product that identifies and eliminates BCMA-expressing malignant and normal cells. CAR specifically recognizes BCMA with a low-immunogenic fully human single chain fragment variable (scFv), promotes CAR-T activation, proliferation, cytokine secretion and target cell killing through the CD3ζ domain, and enhances CAR-T proliferation and persistence through co-stimulatory signaling via 4-1BB.
Trial: NCT05195203
Drug: HS-10353
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single or multiple dose(s) of HS-10353
Trial: NCT04883255
Drug: 10 mg Δ9-tetrahydrocannabinol (THC)
RxNorm normalized name: Δ9-tetrahydrocannabinol
DrugBank: Cannabinol (DB14737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day course of orally-administered THC (dronabinol), 10 mg